# Bundibugyo ebolavirus Type: pathogen Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/bundibugyo-ebolavirus Canonical HTML page: https://getbiobrief.com/entity/bundibugyo-ebolavirus ## Timeline - **2026-08-04**: Leadership Visits and Latest Data Released — Africa CDC Director-General Jean Kaseya visited Bunia, WHO Director-General Tedros arrived in Kinshasa; government update reported 3,802 cases and 1,707 deaths. - **2026-08-03**: Healthcare Workers Issue Ultimatum — In Mongbwalu, healthcare workers threatened to escalate action within 24 hours if unpaid wages were not resolved. - **2026-07-14**: WHO sounds alarm — WHO reports that 80% of new cases are from unknown chains of transmission; striking workers agree to return if paid within 72 hours. - **2026-07-13**: Ethics Approval Received — NanoViricides announces National Ethics Committee approval for Phase II trial of NV-387 oral gummies for Ebola. - **2026-07-13**: Health worker strike — Dozens of healthcare workers at an Ebola treatment centre in Bunia go on strike over unpaid salaries and bonuses. - **2026-07-13**: Staff strike at Rwampara General Hospital — Dozens of workers at the epicenter treatment center strike over two months of unpaid salaries, shutting the facility and blocking roads. - **2026-07-12**: Outbreak Worsens — DRC public health institute reports 1,926 confirmed Ebola cases and 702 deaths, with spread to Haut-Uele and Tshopo provinces. - **2026-07-08**: Virus spreads to two more provinces — Health Minister Kamba announces the outbreak has reached two additional provinces beyond Ituri, further complicating containment. - **2026-07-01**: Experimental treatment study begins — A clinical study of two candidate Ebola treatments launches at a different treatment center in Ituri province, not the one that would later strike. - **2026-06-15**: Uganda Declared Ebola‑Free — Neighboring Uganda discharged its last Ebola patient, ending its own transmission chain linked to the Congo outbreak. - **2026-05-15**: Official outbreak declaration — Congolese authorities declare a Bundibugyo Ebola outbreak after weeks of undetected transmission due to initial misdiagnosis. - **2026-05-15**: Outbreak Declared — Eastern Congo Ebola outbreak officially declared, later linked to Bundibugyo virus. - **2026-05**: Outbreak identified — Congo detects an outbreak of the rare Bundibugyo Ebola virus in the eastern part of the country. ## Recent coverage (5 stories) ### As Ebola Deaths Top 1,700, Biotech Races for Bundibugyo Virus Treatments 2026-08-04 15:58:13 · Sentiment: Strongly negative · Impact: 8/10 · Sources: 6 Congo’s Bundibugyo Ebola outbreak has surged to 3,802 cases and 1,707 deaths, highlighting an urgent need for vaccines and treatments. With no approved products available, two post‑exposure prophylaxis trials in Ituri and two vaccine trials in the UK and Canada are now underway, while nearly 80% of new cases elude contact tracing. Full story: https://getbiobrief.com/story/ebola-deaths-top-1700-bundibugyo-virus-trials ### Ebola Treatment Trial at Risk as Strike Stalls Outbreak Epicenter 2026-08-01 07:48:25 · Sentiment: Neutral · Impact: 5/10 · Sources: 1 Biotech's race to develop therapies for the Bundibugyo Ebola strain faces a new hurdle as a strike at Congo's outbreak epicenter disrupts critical clinical operations. The study of two candidate treatments, launched in early July, could be jeopardized by collapsed workforce morale at nearby facilities. Full story: https://getbiobrief.com/story/ebola-strike-treatment-trial-risk-bio ### Bundibugyo Ebola Outbreak Hits 2,181 Cases with No Vaccine, No Treatment 2026-07-25 03:00:49 · Sentiment: Negative · Impact: 7/10 · Sources: 4 The fastest-growing Ebola outbreak in history is driven by the Bundibugyo virus, which lacks any approved vaccine or therapy. With over 2,100 cases and 864 deaths, biopharma companies face a pressing unmet need and a potential market for rapid filovirus countermeasure development. Full story: https://getbiobrief.com/story/ebola-bundibugyo-vaccine-gap ### 80% of Congo Ebola Cases Untraced: No Approved Vaccine, 702 Dead 2026-07-20 14:52:24 · Sentiment: Strongly negative · Impact: 8/10 · Sources: 2 With 80% of new Ebola cases from unknown chains and the rare Bundibugyo strain lacking any approved vaccine or treatment, this outbreak exposes a critical gap in the biopharma pipeline and may catalyse urgent R&D investment. Full story: https://getbiobrief.com/story/ebola-bundibugyo-outbreak-vaccine-gap ### NNVC's NV-387 Phase II Sets Course as First Oral Ebola Therapy Contender 2026-07-13 19:35:03 · Sentiment: Positive · Impact: 7/10 · Sources: 3 NanoViricides (NYSE American: NNVC) has crossed a major regulatory hurdle with DRC ethics committee approval for its Phase II trial of NV-387 oral gummies for Ebola. The company leverages its nanoviricide platform against an underserved Bundibugyo strain, positioning itself uniquely in the infectious disease space with a potential first-in-class oral antiviral. Full story: https://getbiobrief.com/story/nanoviricides-nnvc-oral-ebola-phase2 --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.